Abstract:Type 2 diabetes mellitus (T2DM) is a metabolic disease with increasing prevalence and mortality year by year. The purpose of this study was to explore new therapeutic targets and candidate drugs for multitargets by single-cell RNA expression profile analysis, network pharmacology, and molecular docking. Single-cell RNA expression profiling of islet β cell samples between T2DM patients and nondiabetic controls was conducted to identify important subpopulations and the marker genes. The potential therapeutic targets of T2DM were identified by the overlap analysis of insulin-related genes and diabetes-related genes, the construction of protein-protein interaction network, and the molecular complex detection (MCODE) algorithm. The network distance method was employed to determine the potential drugs of the target. Molecular docking and molecular dynamic simulations were carried out using AutoDock Vina and Gromacs2019, respectively. Eleven cell clusters were identified by single-cell RNA sequencing (scRNA-seq) data, and three of them (C2, C8, and C10) showed significant differences between T2DM samples and normal samples. Eight genes from differential cell clusters were found from differential cell clusters to be associated with insulin activity and T2DM. The MCODE algorithm built six key subnetworks, with five of them correlating with inflammatory pathways and immune cell infiltration. Importantly, CCR5 was a gene within the key subnetworks and was differentially expressed between normal samples and T2DM samples, with the highest area under the ROC curve (AUC) of 82.5% for the diagnosis model. A total of 49 CCR5-related genes were screened, and DB05494 was identified as the most potential drug with the shortest distance to CCR5-related genes. Molecular docking illustrated that DB05494 stably bound with CCR5 (-8.0 kcal/mol) through multiple hydrogen bonds (LYS26, TYR37, TYR89, CYS178, and GLN280) and hydrophobic bonds (TRP86, PHE112, ILE198, TRP248, and TYR251). This study identified CCR5 as a potential therapeutic target and screened DB05494 as a potential drug for T2DM treatment.

Emerging Roles of ncRNAs in Type 2 Diabetes Mellitus: From Mechanisms to Drug Discovery

Non-Coding RNA as Biomarkers for Type 2 Diabetes Development and Clinical Management

Research Status of Differentially Expressed Noncoding RNAs in Type 2 Diabetes Patients

Long Noncoding RNAs as Diagnostic and Therapeutic Targets in Type 2 Diabetes and Related Complications

Long noncoding RNAs as novel biomarkers for Type 2 diabetes

Emerging roles of microRNAs as diagnostics and potential therapeutic interest in type 2 diabetes mellitus

High-Throughput Sequencing and Exploration of the lncRNA-circRNA-miRNA-mRNA Network in Type 2 Diabetes Mellitus

Non-coding RNAs in Diabetes Mellitus and Diabetic Cardiovascular Disease

Lncrnas: Key Players And Novel Insights Into Diabetes Mellitus

Noncoding RNA in the Regulation of Hepatic Glucose and Lipid Metabolism

Exosomal miRNAs and isomiRs: potential biomarkers for type 2 diabetes mellitus

Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents

Noncoding RNAs as therapeutic targets in atherosclerosis with diabetes mellitus

Roles of non-coding RNA in diabetic cardiomyopathy

NONRATT021972 Long-Noncoding RNA: A Promising Lncrna in Diabetes-Related Diseases

Emerging Role of Long Non-Coding RNAs in Diabetic Vascular Complications

Progress of Micrornas Involved in Type 2 Diabetes Mellitus

Comprehensive Network Analysis Reveals the Targets and Potential Multitarget Drugs of Type 2 Diabetes Mellitus.

The role of ncRNA regulatory mechanisms in diseases—case on gestational diabetes

Regulatory Roles of MicroRNAs in Diabetes

Exploring the design of clinical research studies on the efficacy mechanisms in type 2 diabetes mellitus